FDA proposes withdrawing Amgen's Tavneos in US over efficacy and liver injury concerns

The FDA proposes withdrawing Amgen's Tavneos in the US, questioning its efficacy and citing reports of serious, even fatal, liver injuries. Amgen rejects withdrawing the drug, which will remain available while the regulatory process continues; its sales neared $500 million.

Detected & updated continuously · Source: Nebula